
Jay A Berzofsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2558464/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. Cell Reports Methods, 2022, 2, 100136.	1.4	8
2	BepiTBR: T-B reciprocity enhances B cell epitope prediction. IScience, 2022, 25, 103764.	1.9	9
3	The role of NKT cells in gastrointestinal cancers. Oncolmmunology, 2022, 11, .	2.1	6
4	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
5	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. Cancer Letters, 2021, 499, 279-289.	3.2	7
6	The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination. Frontiers in Immunology, 2021, 12, 638872.	2.2	14
7	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight, 2021, 6, .	2.3	52
8	SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. Frontiers in Immunology, 2021, 12, 658428.	2.2	30
9	A simple, high-throughput method of protein and label removal from extracellular vesicle samples. Nanoscale, 2021, 13, 3737-3745.	2.8	6
10	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. Pathogens, 2021, 10, 138.	1.2	60
11	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	0.6	59
12	Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals. Vaccines, 2021, 9, 1484.	2.1	1
13	Thomas Alexander Waldmann. Immunity, 2021, 54, 2671-2672.	6.6	Ο
14	Complementary approaches to study NKT cells in cancer. Methods in Enzymology, 2020, 631, 371-389.	0.4	1
15	High Sensitivity Protein Gel Electrophoresis Label Compatible with Mass-Spectrometry. Biosensors, 2020, 10, 160.	2.3	4
16	Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity. Journal of Immunology, 2020, 205, 1554-1563.	0.4	8
17	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. Journal of Virology, 2020, 94, .	1.5	7
18	Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development. Frontiers in Immunology, 2020, 11, 315.	2.2	14

#	Article	IF	CITATIONS
19	Synthetic preparation and immunological evaluation of β-mannosylceramide and related N-acyl analogues. Organic and Biomolecular Chemistry, 2020, 18, 2739-2746.	1.5	2
20	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. Journal of Clinical Investigation, 2020, 130, 2789-2799.	3.9	26
21	Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. Oncolmmunology, 2019, 8, e1625687.	2.1	9
22	Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d. Frontiers in Immunology, 2019, 10, 2355.	2.2	5
23	Altered Lipid Tumor Environment and Its Potential Effects on NKT Cell Function in Tumor Immunity. Frontiers in Immunology, 2019, 10, 2187.	2.2	29
24	Highâ€fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. Journal of Extracellular Vesicles, 2019, 8, 1597603.	5.5	83
25	Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate. Frontiers in Immunology, 2019, 10, 1072.	2.2	15
26	Interleukin 21 collaborates with interferon-γ for the optimal expression of interferon-stimulated genes and enhances protection against enteric microbial infection. PLoS Pathogens, 2019, 15, e1007614.	2.1	10
27	The effect of antigen dose on T cell-targeting vaccine outcome. Human Vaccines and Immunotherapeutics, 2019, 15, 407-411.	1.4	36
28	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. Journal of Clinical Investigation, 2019, 129, 1314-1328.	3.9	28
29	IL13Rα2 expression identifies tissueâ€resident ILâ€22â€producing PLZF ⁺ innate TÂcells in the hum liver. European Journal of Immunology, 2018, 48, 1329-1335.	an 1.6	13
30	Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. Cytotherapy, 2018, 20, 728-739.	0.3	4
31	Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. Oncolmmunology, 2018, 7, e1439305.	2.1	6
32	Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity. Journal of Immunology, 2018, 200, ji1701523.	0.4	11
33	Cancer vaccines: translation from mice to human clinical trials. Current Opinion in Immunology, 2018, 51, 111-122.	2.4	39
34	Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunology, Immunotherapy, 2018, 67, 1863-1869.	2.0	38
35	Tissue-Specific Roles of NKT Cells in Tumor Immunity. Frontiers in Immunology, 2018, 9, 1838.	2.2	87
36	Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 2018, 360, .	6.0	931

#	Article	IF	CITATIONS
37	Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naive macaques. Mucosal Immunology, 2018, 11, 1219-1229.	2.7	33
38	Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity. Frontiers in Immunology, 2018, 9, 314.	2.2	15
39	Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry. Sensors, 2018, 18, 2461.	2.1	12
40	Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients. Clinical Cancer Research, 2017, 23, 3352-3364.	3.2	24
41	Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. Scientific Reports, 2017, 7, 1878.	1.6	260
42	Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncolmmunology, 2017, 6, e1308616.	2.1	71
43	Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy. Journal of Immunology, 2017, 198, 3494-3506.	0.4	57
44	Differential T cell homing to colon vs. small intestine is imprinted by local CD11c+ APCs that determine homing receptors. Journal of Leukocyte Biology, 2017, 102, 1381-1388.	1.5	13
45	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Cancer Immunology Research, 2017, 5, 685-694.	1.6	37
46	Role of CD4 TÂcell helper subsets in immune response and deviation of CD8 TÂcells in mice*. European Journal of Immunology, 2017, 47, 2059-2069.	1.6	5
47	Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells Journal of Clinical Oncology, 2017, 35, 3089-3089.	0.8	4
48	Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. PLoS Pathogens, 2017, 13, e1006395.	2.1	24
49	Early SIV Dissemination After Intrarectal SIVmac251 Challenge Was Associated With Proliferating Virus-Susceptible Cells in the Colorectum. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 353-358.	0.9	6
50	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. Oncolmmunology, 2016, 5, e1197459.	2.1	24
51	Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. Cancer Immunology Research, 2016, 4, 354-365.	1.6	114
52	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Seminars in Oncology, 2016, 43, 501-513.	0.8	10
53	Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. Journal of Leukocyte Biology, 2016, 99, 475-482.	1.5	20
54	NKT Cells in Tumor Immunity. , 2016, , 460-469.		2

54 NKT Cells in Tumor Immunity. , 2016, , 460-469.

#	Article	IF	CITATIONS
55	Tumorâ€induced CD11b ⁺ Grâ€1 ⁺ myeloidâ€derived suppressor cells exacerbate immuneâ€mediated hepatitis in mice in a CD40â€dependent manner. European Journal of Immunology, 2015, 45, 1148-1158.	1.6	10
56	Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes. PLoS ONE, 2015, 10, e0143001.	1.1	9
57	Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunology, Immunotherapy, 2015, 64, 437-446.	2.0	104
58	Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells. Journal of Immunology, 2015, 194, 4215-4221.	0.4	60
59	Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. PLoS ONE, 2014, 9, e90353.	1.1	328
60	NKT Cell Networks in the Regulation of Tumor Immunity. Frontiers in Immunology, 2014, 5, 543.	2.2	110
61	Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clinical Immunology, 2014, 155, 91-107.	1.4	24
62	CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy. Cancer Research, 2014, 74, 6771-6783.	0.4	179
63	Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway. Cancer Immunology Research, 2014, 2, 1080-1089.	1.6	131
64	The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer Immunology, Immunotherapy, 2014, 63, 199-213.	2.0	71
65	Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. Clinical Immunology, 2014, 153, 308-322.	1.4	20
66	Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3â^ and CD8+ T Cells. Cancer Immunology Research, 2014, 2, 911-922.	1.6	35
67	Vaccine-induced myeloid cell population dampens protective immunity to SIV. Journal of Clinical Investigation, 2014, 124, 2538-2549.	3.9	58
68	Delicate Balance among Three Types of T Cells in Concurrent Regulation of Tumor Immunity. Cancer Research, 2013, 73, 1514-1523.	0.4	59
69	Balance is a key for happiness. Oncolmmunology, 2013, 2, e24211.	2.1	6
70	IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. Journal of Experimental Medicine, 2013, 210, 491-502.	4.2	190
71	β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy. Clinical Cancer Research, 2013, 19, 4404-4411.	3.2	15
72	Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. Expert Review of Vaccines, 2013, 12, 1115-1118.	2.0	7

#	Article	IF	CITATIONS
73	Oral vaccines. Gut Microbes, 2013, 4, 246-252.	4.3	35
74	Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE. PLoS ONE, 2013, 8, e64365.	1.1	15
75	A push–pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine, 2012, 30, 4323-4327.	1.7	16
76	Improving Immunotherapy: Revisiting the Immunologist's Little Secret. Science Translational Medicine, 2012, 4, 120fs4.	5.8	3
77	Large intestine–targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nature Medicine, 2012, 18, 1291-1296.	15.2	156
78	Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer. Seminars in Oncology, 2012, 39, 348-357.	0.8	36
79	A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy, 2012, 61, 373-384.	2.0	89
80	TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4+ memory T cell loss in SIVmac251-challenged rhesus macaques. Vaccine, 2011, 30, 59-68.	1.7	18
81	Mouse and human iNKT cell agonist \hat{l}^2 -mannosylceramide reveals a distinct mechanism of tumor immunity. Journal of Clinical Investigation, 2011, 121, 683-694.	3.9	41
82	Lack of ILâ€7 and ILâ€15 signaling affects interferonâ€Î³ production by, more than survival of, small intestinal intraepithelial memory CD8 ⁺ T cells. European Journal of Immunology, 2011, 41, 3513-3528.	1.6	7
83	KLF13 sustains thymic memory-like CD8+ T cells in BALB/c mice by regulating IL-4–generating invariant natural killer T cells. Journal of Experimental Medicine, 2011, 208, 1093-1103.	4.2	61
84	A Novel Combination Immunotherapy for Cancer by IL-13Rα2–Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models. Journal of Immunology, 2011, 187, 4935-4946.	0.4	30
85	IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. Journal of Leukocyte Biology, 2011, 90, 205-214.	1.5	12
86	Blockade of TGFâ€Î² enhances tumor vaccine efficacy mediated by CD8 ⁺ T cells. International Journal of Cancer, 2010, 126, 1666-1674.	2.3	72
87	Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9843-9848.	3.3	88
88	Multiple Antigen Peptide Vaccines against <i>Plasmodium falciparum</i> Malaria. Infection and Immunity, 2010, 78, 4613-4624.	1.0	53
89	Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. Journal of Clinical Investigation, 2010, 120, 607-616.	3.9	155
90	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. Journal of Translational Medicine, 2010, 8, 8.	1.8	29

#	Article	IF	CITATIONS
91	Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes. Methods in Microbiology, 2010, 37, 35-66.	0.4	5
92	Pathogenic Roles of CD14, Galectin-3, and OX40 during Experimental Cerebral Malaria in Mice. PLoS ONE, 2009, 4, e6793.	1.1	34
93	Synergistic Enhancement of CD8+ T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody. Clinical Cancer Research, 2009, 15, 6560-6569.	3.2	109
94	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2
95	The Contrasting Roles of NKT Cells in Tumor Immunity. Current Molecular Medicine, 2009, 9, 667-672.	0.6	90
96	Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunology, Immunotherapy, 2008, 57, 907-912.	2.0	29
97	A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunology, Immunotherapy, 2008, 57, 1679-1683.	2.0	50
98	Targeting TARP, a novel breast and prostate tumorâ€associated antigen, with T cell receptorâ€like human recombinant antibodies. European Journal of Immunology, 2008, 38, 1706-1720.	1.6	50
99	Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology, 2008, 381, 106-115.	1.1	50
100	Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay. Journal of Immunological Methods, 2008, 333, 71-78.	0.6	2
101	Commensal DNA Limits Regulatory T Cell Conversion and Is a Natural Adjuvant of Intestinal Immune Responses. Immunity, 2008, 29, 637-649.	6.6	446
102	Regulation of tumor immunity: the role of NKT cells. Expert Opinion on Biological Therapy, 2008, 8, 725-734.	1.4	26
103	Chapter 8 The Role of NKT Cells in Tumor Immunity. Advances in Cancer Research, 2008, 101, 277-348.	1.9	274
104	Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-α2. Cancer Research, 2008, 68, 3467-3475.	0.4	81
105	NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis. Journal of Immunology, 2008, 180, 3627-3635.	0.4	115
106	An Anti–Transforming Growth Factor β Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments. Cancer Research, 2008, 68, 3835-3843.	0.4	203
107	IL-15 Expands Unconventional CD8ααNK1.1+ T Cells but Not Vα14Jα18+ NKT Cells. Journal of Immunology, 2008, 180, 7276-7286.	0.4	22
108	Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16260-16265.	3.3	155

#	Article	IF	CITATIONS
109	lL-15 as a mediator of CD4 ⁺ help for CD8 ⁺ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5201-5206.	3.3	128
110	A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. Clinical Cancer Research, 2008, 14, 4850-4858.	3.2	142
111	Transforming Growth Factor \hat{I}^2 Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17. Cancer Research, 2008, 68, 3915-3923.	0.4	233
112	Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine. Cancer Research, 2008, 68, 1979-1987.	0.4	38
113	Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice. Journal of Virology, 2007, 81, 8774-8783.	1.5	38
114	A Novel Functional CTL Avidity/Activity Compartmentalization to the Site of Mucosal Immunization Contributes to Protection of Macaques against Simian/Human Immunodeficiency Viral Depletion of Mucosal CD4+ T Cells. Journal of Immunology, 2007, 178, 7211-7221.	0.4	93
115	Role of Â3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs. International Immunology, 2007, 19, 1413-1420.	1.8	7
116	Hemagglutinin Protein Is a Primary Target of the Measles Virus–Specific HLAâ€A2–Restricted CD8+T Cell Response during Measles and after Vaccination. Journal of Infectious Diseases, 2007, 195, 1799-1807.	1.9	34
117	Avidity of CD8 T cells sharpens immunodominance. International Immunology, 2007, 19, 497-507.	1.8	38
118	Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis. Journal of Immunology, 2007, 179, 5126-5136.	0.4	187
119	Impact of vaccine-induced mucosal high-avidity CD8+CTLs in delay of AIDS viral dissemination from mucosa. Blood, 2006, 107, 3258-3264.	0.6	127
120	Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. International Journal of Cancer, 2006, 118, 3022-3029.	2.3	28
121	Characterization of a Novel Human Tumor Antigen Interleukin-13 Receptor α2 Chain. Cancer Research, 2006, 66, 4434-4442.	0.4	29
122	Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4 + T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIV KU2 RNA Levels. Journal of Virology, 2006, 80, 3732-3742.	1.5	67
123	Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors. Cancer Research, 2006, 66, 1818-1823.	0.4	37
124	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. Cancer Research, 2006, 66, 11070-11076.	0.4	98
125	CD1d-Restricted Natural Killer T Cells Can Down-regulate Tumor Immunosurveillance Independent of Interleukin-4 Receptor-Signal Transducer and Activator of Transcription 6 or Transforming Growth Factor-β. Cancer Research, 2006, 66, 3869-3875.	0.4	54
126	The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response. Journal of Virology, 2006, 80, 5958-5967.	1.5	39

#	Article	IF	CITATIONS
127	Enhancement of CD8+ T Cell Immunity in the Lung by CpG Oligodeoxynucleotides Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine against Lethal Poxvirus Infection Even in a CD4-Deficient Host. Journal of Immunology, 2006, 177, 6336-6343.	0.4	42
128	Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine. Journal of Immunology, 2006, 176, 3753-3759.	0.4	15
129	Intratumoral Therapy with IL13-PE38 Results in Effective CTL-Mediated Suppression of IL-13Rα2-Expressing Contralateral Tumors. Clinical Cancer Research, 2006, 12, 4678-4686.	3.2	20
130	Possible Therapeutic Vaccine Strategy against Human Immunodeficiency Virus Escape from Reverse Transcriptase Inhibitors Studied in HLA-A2 Transgenic Mice. Journal of Virology, 2006, 80, 10645-10651.	1.5	12
131	Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nature Medicine, 2005, 11, 1238-1243.	15.2	366
132	Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. International Journal of Cancer, 2005, 114, 80-87.	2.3	88
133	Immunization With Mutant p53- and K-ras–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome. Journal of Clinical Oncology, 2005, 23, 5099-5107.	0.8	167
134	Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. Journal of Experimental Medicine, 2005, 201, 139-148.	4.2	636
135	Expression of Interleukin-4 by Recombinant Respiratory Syncytial Virus Is Associated with Accelerated Inflammation and a Nonfunctional Cytotoxic T-Lymphocyte Response following Primary Infection but Not following Challenge with Wild-Type Virus. Journal of Virology, 2005, 79, 9515-9526.	1.5	26
136	Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas. Journal of Immunology, 2005, 174, 4228-4236.	0.4	80
137	A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. Journal of Experimental Medicine, 2005, 202, 1627-1633.	4.2	262
138	Selecting stable molecular targets for treatment and prevention of AIDS. Genome Informatics, 2005, 16, 254-61.	0.4	1
139	Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells. Cancer Research, 2004, 64, 2610-2618.	0.4	70
140	IL-15/IL-15RÂ-mediated avidity maturation of memory CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15154-15159.	3.3	123
141	Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8 + T-Cell Peptide Epitope of Vaccinia and Variola Viruses. Journal of Virology, 2004, 78, 7052-7060.	1.5	101
142	Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice. Cancer Research, 2004, 64, 8022-8028.	0.4	86
143	Immunoregulatory T cells in tumor immunity. Current Opinion in Immunology, 2004, 16, 157-162.	2.4	237
144	Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunology, Immunotherapy, 2004, 53, 79-85.	2.0	181

#	Article	IF	CITATIONS
145	Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. International Journal of Cancer, 2004, 111, 298-302.	2.3	34
146	Mucosal AIDS vaccines: current status and future directions. Expert Review of Vaccines, 2004, 3, S65-S73.	2.0	30
147	Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. Journal of Clinical Investigation, 2004, 113, 998-1007.	3.9	182
148	Immunobiology of Mucosal HIV Infection and the Basis for Development of a New Generation of Mucosal AIDS Vaccines. Immunity, 2004, 20, 247-253.	6.6	125
149	Progress on new vaccine strategies for the immunotherapy and prevention of cancer. Journal of Clinical Investigation, 2004, 113, 1515-1525.	3.9	175
150	Progress on new vaccine strategies against chronic viral infections. Journal of Clinical Investigation, 2004, 114, 450-462.	3.9	68
151	Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity. Journal of Immunology, 2003, 171, 5842-5852.	0.4	87
152	Cellular Immune Responses to Human Papillomavirus (HPV)–16 L1 in Healthy Volunteers Immunized with Recombinant HPVâ€16 L1 Virusâ€Like Particles. Journal of Infectious Diseases, 2003, 188, 327-338.	1.9	159
153	Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3392-3397.	3.3	174
154	Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC. Journal of Immunology, 2003, 170, 2523-2530.	0.4	120
155	Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance. Journal of Experimental Medicine, 2003, 198, 1741-1752.	4.2	508
156	Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9458-9463.	3.3	263
157	Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressing HIV-1 Antigen. Journal of Immunology, 2003, 171, 2548-2555.	0.4	33
158	Molecular Mechanisms and Biological Significance of CTL Avidity. Current HIV Research, 2003, 1, 287-294.	0.2	71
159	Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines. Current Molecular Medicine, 2003, 3, 285-301.	0.6	75
160	Effects of Cytotoxic T Lymphocytes (CTL) Directed against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 Infection. Journal of Virology, 2002, 76, 10507-10511.	1.5	52
161	Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. Methods in Microbiology, 2002, 32, 99-123.	0.4	1
162	Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-Î ³ Dependent. Journal of Immunology, 2002, 169, 5796-5804.	0.4	109

#	Article	IF	CITATIONS
163	A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13020-13025.	3.3	89
164	Rapid Induction of Apoptosis in CD8+ HIV-1 Envelope-Specific Murine CTLs by Short Exposure to Antigenic Peptide. Journal of Immunology, 2002, 169, 6588-6593.	0.4	25
165	DNA vaccines encoding human immunodeficiency virus–1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood, 2002, 100, 1153-1159.	0.6	127
166	Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity to malaria. Parasite Immunology, 2002, 20, 263-278.	0.7	28
167	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. Journal of Clinical Oncology, 2001, 19, 1848-1854.	0.8	113
168	An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8+ CTL. European Journal of Immunology, 2001, 31, 2951-2959.	1.6	27
169	Impaired development of HIV-1 gp160-specific CD8+ cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice withHelicobacter pylori infection. European Journal of Immunology, 2001, 31, 516-526.	1.6	2
170	Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. International Immunology, 2001, 13, 897-908.	1.8	73
171	Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. Microbes and Infection, 2001, 3, 1051-1061.	1.0	27
172	Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Medicine, 2001, 7, 1320-1326.	15.2	231
173	Strategies for designing and optimizing new generation vaccines. Nature Reviews Immunology, 2001, 1, 209-219.	10.6	319
174	Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antibody. Journal of Immunology, 2001, 167, 699-707.	0.4	8
175	Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. International Immunology, 2001, 13, 817-824.	1.8	61
176	High-Avidity CTL Exploit Two Complementary Mechanisms to Provide Better Protection Against Viral Infection Than Low-Avidity CTL. Journal of Immunology, 2001, 166, 1690-1697.	0.4	196
177	Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites. Journal of Immunology, 2001, 167, 1584-1591.	0.4	100
178	Counter-regulation of cytolytic activity and cytokine production in HIV-1-specific murine CD8+ cytotoxic T lymphocytes by free antigenic peptide. International Immunology, 2001, 13, 43-51.	1.8	6
179	Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-1± synergize for IL-12R expression at low antigen dose. International Immunology, 2001, 13, 1433-1442.	1.8	25
180	Impairment of Gag-Specific CD8 + T-Cell Function in Mucosal and Systemic Compartments of Simian Immunodeficiency Virus mac251- and Simian-Human Immunodeficiency Virus KU2-Infected Macaques. Journal of Virology, 2001, 75, 11483-11495.	1.5	67

#	Article	IF	CITATIONS
181	Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates. Journal of Virology, 2001, 75, 4430-4434.	1.5	59
182	Granulocyte-Macrophage Colony-Stimulating Factor Expressed by Recombinant Respiratory Syncytial Virus Attenuates Viral Replication and Increases the Level of Pulmonary Antigen-Presenting Cells. Journal of Virology, 2001, 75, 12128-12140.	1.5	74
183	High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. Journal of Clinical Investigation, 2001, 108, 1677-1685.	3.9	72
184	Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes. Aids, 2000, 14, 1497-1506.	1.0	11
185	NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway. Nature Immunology, 2000, 1, 515-520.	7.0	639
186	Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed with an Antigenic Peptide: Similarities to a T Cell Receptor with the Same Specificity. Journal of Immunology, 2000, 165, 5703-5712.	0.4	29
187	Characterization of Conserved T- and B-Cell Epitopes in Plasmodium falciparum Major Merozoite Surface Protein 1. Infection and Immunity, 2000, 68, 2685-2691.	1.0	26
188	Interplay of Cytokines and Adjuvants in the Regulation of Mucosal and Systemic HIV-Specific CTL. Journal of Immunology, 2000, 165, 6454-6462.	0.4	85
189	HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. Aids, 1999, 13, 2003-2012.	1.0	44
190	Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunological Reviews, 1999, 170, 151-172.	2.8	94
191	Effect of Zidovudine Postexposure Prophylaxis on the Development of HIV-Specific Cytotoxic T-Lymphocyte Responses in HIV-Exposed Healthcare Workers. Infection Control and Hospital Epidemiology, 1999, 20, 428-430.	1.0	17
192	Supraoptimal Peptide–Major Histocompatibility Complex Causes a Decrease in Bcl-2 Levels and Allows Tumor Necrosis Factor α Receptor II–mediated Apoptosis of Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 1998, 188, 1391-1399.	4.2	89
193	Molecular Alterations in Pediatric Sarcomas: Potential Targets for Immunotherapy. Sarcoma, 1998, 2, 77-87.	0.7	18
194	Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein. Journal of Virology, 1998, 72, 8264-8272.	1.5	105
195	Target Cell Lysis by CTL Granule Exocytosis Is Independent of ICE/Ced-3 Family Proteases. Immunity, 1997, 6, 209-215.	6.6	210
196	Cytotoxic T lymphocyte (CTL) adherence assay (CAA): a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. Journal of Immunological Methods, 1997, 201, 1-10.	0.6	4
197	Structural comparison of a 15 residue peptide from the V3 loop of HIV-1111band an O-glycosylated analogue. FEBS Letters, 1996, 393, 280-286.	1.3	35
198	Dendritic Cells in Antitumor Immune Responses. Cellular Immunology, 1996, 170, 111-119.	1.4	199

#	Article	IF	CITATIONS
199	Prediction of HIV Peptide Epitopes by a Novel Algorithm. AIDS Research and Human Retroviruses, 1996, 12, 593-610.	0.5	41
200	Candidate HIV Type 1 Multideterminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, All Using the Same Adjuvant Immunization. AIDS Research and Human Retroviruses, 1996, 12, 259-272.	0.5	49
201	Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human cytotoxic T lymphocytes. International Immunology, 1996, 8, 641-649.	1.8	33
202	Designing Peptide Vaccines to Broaden Recognition and Enhance Potency. Annals of the New York Academy of Sciences, 1995, 754, 161-168.	1.8	24
203	Binding of Glycoprotein 120 and Peptides from the HIV-1 Envelope by Autoantibodies in Mice with Experimentally Induced Systemic Lupus Erythematosus and in Patients with the Disease. AIDS Research and Human Retroviruses, 1994, 10, 1071-1077.	0.5	29
204	Increased susceptibility of mice infected withSchistosoma mansoni to recombinant vaccinia virus: Association of viral persistence with egg granuloma formation. European Journal of Immunology, 1994, 24, 3050-3056.	1.6	52
205	Minimal requirements for peptide mediated activation of CD8+ CTL. Molecular Immunology, 1994, 31, 1285-1293.	1.0	66
206	Sequence features that correlate with MHC restriction. Molecular Immunology, 1994, 31, 1-19.	1.0	34
207	Fcε receptor-positive cells are a major source of antigen-induced interleukin-4 in spleens of mice infected withSchistosoma mansoni. European Journal of Immunology, 1993, 23, 1910-1916.	1.6	54
208	Epitope Selection and Design of Synthetic Vaccines Molecular Approaches to Enhancing Immunogenicity and Cross-Reactivity of Engineered Vaccines. Annals of the New York Academy of Sciences, 1993, 690, 256-264.	1.8	48
209	Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. International Immunology, 1993, 5, 849-857.	1.8	142
210	Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules. International Immunology, 1993, 5, 1129-1138.	1.8	17
211	Cell-Mediated Immune Response to Human Immunodeficiency Virus (HIV) Type 1 in Seronegative Homosexual Men with Recent Sexual Exposure to HIV-1. Journal of Infectious Diseases, 1992, 165, 1012-1019.	1.9	396
212	Role of T-Cell Derived Cytokines in the Downregulation of Immune Responses in Parasitic and Retroviral Infection. Immunological Reviews, 1992, 127, 183-204.	2.8	484
213	Mechanisms of T cell recognition with application to vaccine design. Molecular Immunology, 1991, 28, 217-223.	1.0	19
214	Development of artificial vaccines against HIV using defined epitopes. FASEB Journal, 1991, 5, 2412-2418.	0.2	54
215	Excess β2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature, 1991, 349, 74-77.	13.7	128
216	Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. European Journal of Immunology, 1991, 21, 1345-1349.	1.6	45

#	Article	IF	CITATIONS
217	Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals. Journal of Clinical Immunology, 1991, 11, 143-151.	2.0	10
218	Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature, 1990, 344, 873-875.	13.7	505
219	Repeated determinants within the retinal interphotoreceptor retinoid-binding protein (IRBP): Immunological properties of the repeats of an immunodominant determinant. Cellular Immunology, 1990, 126, 331-342.	1.4	18
220	Characterization of a helper T cell epitope recognized by mice of a low responder major histocompatibility type. Molecular Immunology, 1990, 27, 941-946.	1.0	5
221	[40] Identification of T-cell epitopes and use in construction of synthetic vaccines. Methods in Enzymology, 1989, 178, 611-634.	0.4	29
222	Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature, 1989, 339, 383-385.	13.7	232
223	Immune responses to peptides derived from the retinal protein IRBP: Immunopathogenic determinants are not necessarily immunodominant. Clinical Immunology and Immunopathology, 1989, 53, 212-224.	2.1	15
224	Immunodominance in T lymphocyte recognition. Immunology Letters, 1988, 18, 83-92.	1.1	73
225	Antigen Processing for Presentation to T Lymphocytes: Function, Mechanisms, and Implications for the T-Cell Repertoire. Immunological Reviews, 1988, 106, 5-31.	2.8	107
226	Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature, 1988, 334, 258-260.	13.7	201
227	Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature, 1988, 334, 706-708.	13.7	158
228	Antigenic structures recognized by T cells. Aids, 1988, 2, S95-102.	1.0	11
229	Plasmodium falciparum: Sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine. Experimental Parasitology, 1987, 64, 64-70.	0.5	27
230	Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. Journal of Molecular Biology, 1987, 195, 659-685.	2.0	627
231	Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: Mechanisms of activation and killing. Cellular Immunology, 1987, 105, 301-316.	1.4	48
232	Protein Antigenic Structures Recognized by T Cells; Potential Applications to Vaccine Design. Immunological Reviews, 1987, 98, 9-52.	2.8	144
233	Myoglobin adsorption onto crosslinked polydimethylsiloxane. Journal of Colloid and Interface Science, 1986, 111, 466-474.	5.0	21
234	How many class II immune response genes? A reappraisal of the evidence. Immunogenetics, 1986, 23, 302-308.	1.2	13

#	Article	IF	CITATIONS
235	CORRELATION OF INTRATHYMIC TOLERANCE WITH INTRATHYMIC CHIMERISM IN NEONATALLY TOLERIZED MICE. Transplantation, 1985, 40, 68-72.	0.5	30
236	A unidirectional carrier effect. Cellular Immunology, 1985, 92, 226-234.	1.4	1
237	An la-restricted epitope-specific circuit regulating T cell-B cell interaction and antibody specificity. Survey of Immunologic Research, 1983, 2, 223-229.	0.4	71
238	Genetic control of the immune response to staphylococcal nuclease. Seminars in Immunopathology, 1978, 1, 51-83.	4.0	33
239	Studies on oxidative drug metabolism in thefull-term newborn infant. Journal of Pediatrics, 1966, 69, 1139-1149.	0.9	30